Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""DNA Repair Enzymes"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 142
Tytuł:
MGMT ProFWise: Unlocking a New Application for Combined Feature Selection and the Rank-Based Weighting Method to Link MGMT Methylation Status to Serum Protein Expression in Patients with Glioblastoma.
Autorzy:
Tasci E; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Shah Y; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
Jagasia S; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Zhuge Y; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Shephard J; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Johnson MO; Department of Neurosurgery, Duke University, Durham, NC 27710, USA.; National Tele-Oncology, Veterans Health Administration, Durham, NC 27710, USA.
Elemento O; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
Joyce T; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Chappidi S; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Cooley Zgela T; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Sproull M; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Mackey M; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Camphausen K; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Krauze AV; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Apr 06; Vol. 25 (7). Date of Electronic Publication: 2024 Apr 06.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/genetics
Brain Neoplasms*/genetics
Humans ; Proteomics ; Temozolomide/therapeutic use ; Blood Proteins ; O(6)-Methylguanine-DNA Methyltransferase ; DNA Modification Methylases/genetics ; Tumor Suppressor Proteins/genetics ; DNA Repair Enzymes/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM].
Autorzy:
Gibson D; Department of Neuro-Oncology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.; Department of Bioinformatics, University of California, Los Angeles, Los Angeles, CA, USA.
Vo AH; Department of Neuro-Oncology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA. .
Lambing H; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
Bhattacharya P; Department of Neuro-Oncology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.
Tahir P; University of California, San Francisco Library, San Francisco, CA, USA.
Chehab FF; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Butowski N; Department of Neuro-Oncology, University of California, San Francisco, 400 Parnassus Ave, San Francisco, CA, USA.
Pokaż więcej
Źródło:
BMC neurology [BMC Neurol] 2024 Mar 23; Vol. 24 (1), pp. 103. Date of Electronic Publication: 2024 Mar 23.
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Brain Neoplasms*/genetics
Glioblastoma*/genetics
Glioma*/genetics
Humans ; DNA Methylation/genetics ; DNA Modification Methylases/genetics ; DNA Repair Enzymes/genetics ; Prognosis ; Tumor Suppressor Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Development of A Radiomic Model for MGMT Promoter Methylation Detection in Glioblastoma Using Conventional MRI.
Autorzy:
Doniselli FM; Neuroradiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.; Department of Biomedical Sciences for Health, Università Degli Studi di Milano, 20133 Milan, Italy.
Pascuzzo R; Neuroradiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Agrò M; Post-Graduate School in Radiodiagnostics, Università Degli Studi di Milano, 20122 Milan, Italy.
Aquino D; Neuroradiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Anghileri E; Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Farinotti M; Neuroepidemiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Pollo B; Neuropathology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Paterra R; Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Cuccarini V; Neuroradiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Moscatelli M; Neuroradiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.; Department of Biomedical Sciences for Health, Università Degli Studi di Milano, 20133 Milan, Italy.
DiMeco F; Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.; Department of Oncology and Hematology-Oncology, Università Degli Studi di Milano, 20122 Milan, Italy.; Department of Neurological Surgery, Johns Hopkins Medical School, Baltimore, MD 21205, USA.
Sconfienza LM; Department of Biomedical Sciences for Health, Università Degli Studi di Milano, 20133 Milan, Italy.; Radiology Unit, IRCCS Istituto Ortopedico Galeazzi, 20157 Milan, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 21; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 21.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/diagnostic imaging
Glioblastoma*/genetics
Humans ; Radiomics ; Retrospective Studies ; Magnetic Resonance Imaging ; Algorithms ; O(6)-Methylguanine-DNA Methyltransferase ; DNA Modification Methylases/genetics ; Tumor Suppressor Proteins/genetics ; DNA Repair Enzymes/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Autorzy:
Wu Q; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Berglund AE; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Macaulay RJ; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Etame AB; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 14; Vol. 24 (20). Date of Electronic Publication: 2023 Oct 14.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Glioblastoma*/pathology
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Brain Neoplasms*/pathology
Humans ; Temozolomide/pharmacology ; Temozolomide/therapeutic use ; Dacarbazine/pharmacology ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Alkylating/therapeutic use ; DNA Methylation ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; O(6)-Methylguanine-DNA Methyltransferase/genetics ; Epigenesis, Genetic ; Cell Line, Tumor ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.
Autorzy:
Leske H; Department of Pathology, Oslo University Hospital, Oslo, Norway. .; University of Oslo (UiO), Oslo, Norway. .; Department of Neuropathology, University Hospital of Zurich, Zurich, Switzerland. .
Camenisch Gross U; Department of Pathology, University Hospital of Zurich, Zurich, Switzerland.
Hofer S; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Neidert MC; Department of Neurosurgery, University Hospital of Zurich, Zurich, Switzerland.; Department of Neurosurgery, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland.
Leske S; University of Oslo (UiO), Oslo, Norway.
Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Lehnick D; Department of Health Sciences and Medicine, Head Biostatistics and Methodology, University of Lucerne, Lucerne, Switzerland.
Rushing EJ; Department of Neuropathology, University Hospital of Zurich, Zurich, Switzerland.; Department of Pathology/ Neuropathology, Lucerne, Switzerland.
Pokaż więcej
Źródło:
Acta neuropathologica communications [Acta Neuropathol Commun] 2023 Aug 28; Vol. 11 (1), pp. 139. Date of Electronic Publication: 2023 Aug 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/genetics
Glioblastoma*/therapy
Humans ; Prognosis ; Temozolomide/therapeutic use ; Methylation ; Prospective Studies ; Retrospective Studies ; Isocitrate Dehydrogenase/genetics ; DNA Modification Methylases/genetics ; Tumor Suppressor Proteins/genetics ; DNA Repair Enzymes/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma.
Autorzy:
Zappe K; Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Pühringer K; Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Pflug S; Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Berger D; Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Böhm A; Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Spiegl-Kreinecker S; Department of Neurosurgery, Kepler University Hospital GmbH, Johannes Kepler University, 4040 Linz, Austria.
Cichna-Markl M; Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Jun 15; Vol. 12 (12). Date of Electronic Publication: 2023 Jun 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Brain Neoplasms*/metabolism
Glioblastoma*/metabolism
Humans ; DNA Methylation/genetics ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; Promoter Regions, Genetic/genetics ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.
Autorzy:
Hasan H; Interdisciplinary Brain Research Centre, Faculty of Medicine, Aligarh Muslim University, Aligarh 202002, India.
Afzal M; Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, India.
Castresana JS; Department of Biochemistry and Genetics, University of Navarra School of Sciences, 31008 Pamplona, Spain.
Shahi MH; Interdisciplinary Brain Research Centre, Faculty of Medicine, Aligarh Muslim University, Aligarh 202002, India.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Jun 07; Vol. 12 (12). Date of Electronic Publication: 2023 Jun 07.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Glioblastoma*/pathology
MicroRNAs*/metabolism
Humans ; Dacarbazine/therapeutic use ; Antineoplastic Agents, Alkylating/therapeutic use ; DNA Repair Enzymes/metabolism ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; DNA Modification Methylases/therapeutic use ; Temozolomide/therapeutic use ; DNA Methylation/genetics ; Epigenesis, Genetic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
Autorzy:
Wu M; College of Pharmacy, Dalian Medical University, Dalian 116044, China.; College of Basic Medical Science, Dalian Medical University, Dalian 116044, China.
Song D; College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Li H; College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Ahmad N; College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Xu H; College of Basic Medical Science, Dalian Medical University, Dalian 116044, China.
Yang X; College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Wang Q; College of Basic Medical Science, Dalian Medical University, Dalian 116044, China.
Cheng X; College of Basic Medical Science, Dalian Medical University, Dalian 116044, China.
Deng S; College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Shu X; College of Pharmacy, Dalian Medical University, Dalian 116044, China.; Key Laboratory for Basic and Applied Research on Pharmacodynamic Substances of Traditional Chinese Medicine of Liaoning Province, Dalian Medical University, Dalian 116044, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 May 29; Vol. 24 (11). Date of Electronic Publication: 2023 May 29.
Typ publikacji:
Journal Article
MeSH Terms:
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Glioblastoma*/pathology
Humans ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Alkylating/therapeutic use ; Cell Line, Tumor ; DNA Modification Methylases/genetics ; DNA Repair Enzymes/genetics ; Drug Resistance, Neoplasm ; Molecular Chaperones/pharmacology ; Protein Inhibitors of Activated STAT ; Resveratrol/pharmacology ; Resveratrol/therapeutic use ; STAT3 Transcription Factor/metabolism ; Suppressor of Cytokine Signaling Proteins/metabolism ; Temozolomide/pharmacology ; Temozolomide/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Autorzy:
Brawanski KR; Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Sprung S; Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Freyschlag CF; Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Hoeftberger R; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.
Ströbel T; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.
Haybaeck J; Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Diagnostic and Research Center for Molecular Biomedicine, Diagnostic and Research Institute of Pathology, Medical University of Graz, 8036 Graz, Austria.
Thomé C; Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Manzl C; Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Birkl-Toeglhofer AM; Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Mar 24; Vol. 24 (7). Date of Electronic Publication: 2023 Mar 24.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Brain Neoplasms*/metabolism
Adult ; Aged ; Humans ; Temozolomide/pharmacology ; Temozolomide/therapeutic use ; Progression-Free Survival ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Alkylating/therapeutic use ; Dacarbazine/pharmacology ; Dacarbazine/therapeutic use ; Methylation ; DNA Mismatch Repair ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; O(6)-Methylguanine-DNA Methyltransferase/genetics ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; DNA Methylation ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Radiogenomic classification for MGMT promoter methylation status using multi-omics fused feature space for least invasive diagnosis through mpMRI scans.
Autorzy:
Qureshi SA; Department of Computer and Information Sciences, Pakistan Institute of Engineering and Applied Sciences, Islamabad, Pakistan. .
Hussain L; Department of Computer Science and IT, Neelum Campus, The University of Azad Jammu and Kashmir, Muzaffarabad, Azad Kashmir, Pakistan. lall_.; Department of Computer Science and IT, King Abdullah Campus, The University of Azad Jammu and Kashmir, Muzaffarabad, Azad Kashmir, Pakistan. lall_.; Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA. lall_.
Ibrar U; Farooq Hospital, Lahore, Pakistan.
Alabdulkreem E; Department of Computer Sciences, College of Computer and Information Sciences, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia.
Nour MK; Department of Computer Sciences, College of Computing and Information System, Umm Al-Qura University, Mecca, Saudi Arabia.
Alqahtani MS; Radiological Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha, 61421, Saudi Arabia.
Nafie FM; Department of Computer Science, College of Science and Humanities at Alghat, Majmaah University, Al-Majmaah, 11952, Saudi Arabia.
Mohamed A; Research Centre, Future University in Egypt, New Cairo, 11845, Egypt.
Mohammed GP; Department of Computer and Self Development, Preparatory Year Deanship, Prince Sattam Bin Abdulaziz University, AlKharj, Saudi Arabia.
Duong TQ; Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Feb 25; Vol. 13 (1), pp. 3291. Date of Electronic Publication: 2023 Feb 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/diagnostic imaging
Glioblastoma*/genetics
Multiparametric Magnetic Resonance Imaging*
Brain Neoplasms*/diagnostic imaging
Brain Neoplasms*/genetics
Humans ; Multiomics ; DNA Methylation/genetics ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; Magnetic Resonance Imaging/methods ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines.
Autorzy:
Brandt B; Department of Medical Biology and Central Electron Microscopic Laboratory, Medical School, University of Pécs, 7624 Pécs, Hungary.
Németh M; Department of Medical Biology and Central Electron Microscopic Laboratory, Medical School, University of Pécs, 7624 Pécs, Hungary.
Berta G; Department of Medical Biology and Central Electron Microscopic Laboratory, Medical School, University of Pécs, 7624 Pécs, Hungary.
Szünstein M; Department of Ecology, Faculty of Sciences, University of Pécs, 7624 Pécs, Hungary.
Heffer M; Department of Medical Biology and Genetics, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
Rauch TA; Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, 7624 Pécs, Hungary.
Pap M; Department of Medical Biology and Central Electron Microscopic Laboratory, Medical School, University of Pécs, 7624 Pécs, Hungary.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 27; Vol. 24 (9). Date of Electronic Publication: 2023 Apr 27.
Typ publikacji:
Journal Article
MeSH Terms:
Glioblastoma*/metabolism
Brain Neoplasms*/pathology
Humans ; Temozolomide/pharmacology ; Temozolomide/therapeutic use ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Alkylating/therapeutic use ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; DNA Modification Methylases/genetics ; DNA Repair Enzymes/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions.
Autorzy:
Blakstad H; Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Brekke J; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
Rahman MA; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.; Institute for Biomedicine, University of Bergen, Bergen, Norway.
Arnesen VS; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.; Institute for Biomedicine, University of Bergen, Bergen, Norway.
Miletic H; Institute for Biomedicine, University of Bergen, Bergen, Norway.; Department of Pathology, Haukeland University Hospital, Bergen, Norway.
Brandal P; Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Lie SA; Institute for Clinical Dentistry, University of Bergen, Bergen, Norway.
Chekenya M; Institute for Biomedicine, University of Bergen, Bergen, Norway.
Goplen D; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Feb 02; Vol. 18 (2), pp. e0281166. Date of Electronic Publication: 2023 Feb 02 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/therapy
Glioblastoma*/drug therapy
Brain Neoplasms*/therapy
Brain Neoplasms*/drug therapy
Humans ; Prognosis ; Neoplasm Recurrence, Local/genetics ; Temozolomide/therapeutic use ; DNA Methylation ; Retrospective Studies ; DNA Modification Methylases/genetics ; Antineoplastic Agents, Alkylating/therapeutic use ; DNA Repair Enzymes/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting brain cancer.
Autorzy:
Reddel R; Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Aref A; Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Jul 29; Vol. 377 (6605), pp. 467-468. Date of Electronic Publication: 2022 Jul 28.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
DNA Modification Methylases*/genetics
DNA Repair*/genetics
DNA Repair Enzymes*/genetics
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Tumor Suppressor Proteins*/genetics
DNA Methylation ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mechanism-based design of agents that selectively target drug-resistant glioma.
Autorzy:
Lin K; Department of Chemistry, Yale University, New Haven, CT 06520, USA.; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.; Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Gueble SE; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.
Sundaram RK; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.
Huseman ED; Department of Chemistry, Yale University, New Haven, CT 06520, USA.
Bindra RS; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.; Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Herzon SB; Department of Chemistry, Yale University, New Haven, CT 06520, USA.; Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Jul 29; Vol. 377 (6605), pp. 502-511. Date of Electronic Publication: 2022 Jul 28.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Alkylating*/chemistry
Antineoplastic Agents, Alkylating*/pharmacology
Antineoplastic Agents, Alkylating*/therapeutic use
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
DNA Modification Methylases*/genetics
DNA Repair Enzymes*/genetics
Drug Design*
Drug Resistance, Neoplasm*/genetics
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Tumor Suppressor Proteins*/genetics
Cell Line, Tumor ; DNA Methylation/genetics ; DNA Repair/genetics ; Dacarbazine/pharmacology ; Dacarbazine/therapeutic use ; Humans ; Temozolomide/pharmacology ; Temozolomide/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Diagnostic and therapeutic challenges of glioblastoma as an initial malignancy of constitutional mismatch repair deficiency (CMMRD): two case reports and a literature review.
Autorzy:
Onishi S; Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.; Department of Neurosurgery, Kure Medical Center and Chugoku Cancer Center, National Hospital Organization, Hiroshima, Japan.
Yamasaki F; Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kuraoka K; Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Taguchi A; Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takayasu T; Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Akagi K; Department of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
Hinoi T; Department of Clinical and Molecular Genetics, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. .
Pokaż więcej
Źródło:
BMC medical genomics [BMC Med Genomics] 2023 Jan 16; Vol. 16 (1), pp. 6. Date of Electronic Publication: 2023 Jan 16.
Typ publikacji:
Review; Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/diagnosis
Glioblastoma*/genetics
Brain Neoplasms*/diagnosis
Brain Neoplasms*/genetics
Brain Neoplasms*/metabolism
Colorectal Neoplasms*/genetics
Male ; Child ; Female ; Humans ; Mismatch Repair Endonuclease PMS2/genetics ; Mismatch Repair Endonuclease PMS2/metabolism ; Endothelial Cells/metabolism ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; DNA Repair Enzymes/therapeutic use
SCR Disease Name:
Turcot syndrome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation.
Autorzy:
Lakis NS; Department of Pathology, Kansas University Medical Center, Kansas City, KS, USA.; Department of Pathology and Laboratory Medicine, Lifespan Academic Medical Center, Providence, Rhode Island, USA.; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Brodsky AS; Department of Pathology and Laboratory Medicine, Lifespan Academic Medical Center, Providence, Rhode Island, USA.; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.; Center for Computational Molecular Biology, Brown University, Providence, Rhode Island, USA.
Karashchuk G; Department of Pathology and Laboratory Medicine, Lifespan Academic Medical Center, Providence, Rhode Island, USA.; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Audesse AJ; Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island, USA.
Yang D; Department of Pathology and Laboratory Medicine, Lifespan Academic Medical Center, Providence, Rhode Island, USA.
Sturtevant A; Department of Pathology and Laboratory Medicine, Lifespan Academic Medical Center, Providence, Rhode Island, USA.
Lombardo K; Department of Pathology and Laboratory Medicine, Lifespan Academic Medical Center, Providence, Rhode Island, USA.
Wong IY; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.; School of Engineering, Brown University, Providence, Rhode Island, USA.
Webb AE; Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island, USA.; Center on Biology of Aging, Brown University, Providence, Rhode Island, USA.; Carney Institute for Brain Science, Brown University, Providence, Rhode Island, USA.
Anthony DC; Department of Pathology and Laboratory Medicine, Lifespan Academic Medical Center, Providence, Rhode Island, USA. douglas_.; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. douglas_.; Carney Institute for Brain Science, Brown University, Providence, Rhode Island, USA. douglas_.; Department of Neurology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. douglas_.
Pokaż więcej
Źródło:
Acta neuropathologica communications [Acta Neuropathol Commun] 2022 Nov 04; Vol. 10 (1), pp. 159. Date of Electronic Publication: 2022 Nov 04.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/pathology
Brain Neoplasms*/pathology
Humans ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism ; DNA Methylation ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Prognosis ; Phenotype ; Stem Cells/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis.
Autorzy:
Sareen H; Centre for Circulating Tumour Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.; South-Western Clinical School, University of New South Wales, Liverpool, NSW 2170, Australia.
Ma Y; Centre for Circulating Tumour Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.; South-Western Clinical School, University of New South Wales, Liverpool, NSW 2170, Australia.
Becker TM; Centre for Circulating Tumour Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.; South-Western Clinical School, University of New South Wales, Liverpool, NSW 2170, Australia.; School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Roberts TL; Centre for Circulating Tumour Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.; South-Western Clinical School, University of New South Wales, Liverpool, NSW 2170, Australia.; School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
de Souza P; South-Western Clinical School, University of New South Wales, Liverpool, NSW 2170, Australia.; School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.; Liverpool Hospital, Liverpool, NSW 2170, Australia.
Powter B; Centre for Circulating Tumour Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Aug 09; Vol. 23 (16). Date of Electronic Publication: 2022 Aug 09.
Typ publikacji:
Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms:
Brain Neoplasms*/metabolism
Glioblastoma*/drug therapy
Biomarkers/metabolism ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; DNA Methylation ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; Humans ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach.
Autorzy:
Do DT; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 15th Floor, No. 172-1, Keelung Rd., Sect. 2, Da-an District, Taipei, 106, Taiwan, ROC.
Yang MR; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 15th Floor, No. 172-1, Keelung Rd., Sect. 2, Da-an District, Taipei, 106, Taiwan, ROC.; Department of Electrical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan, ROC.
Lam LHT; International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC.
Le NQK; Professional Master Program in Artificial Intelligence in Medicine, College of Medicine, Taipei Medical University, 19th Floor, No. 172-1, Keelung Rd., Sect. 2, Da-an District, Taipei, 106, Taiwan, ROC. .; Research Center for Artificial Intelligence in Medicine, Taipei Medical University, Taipei, Taiwan, ROC. .; Translational Imaging Research Center, Taipei Medical University Hospital, Taipei, Taiwan, ROC. .
Wu YW; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 15th Floor, No. 172-1, Keelung Rd., Sect. 2, Da-an District, Taipei, 106, Taiwan, ROC. .; Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan, ROC. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Aug 04; Vol. 12 (1), pp. 13412. Date of Electronic Publication: 2022 Aug 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Brain Neoplasms*/diagnostic imaging
Brain Neoplasms*/genetics
Brain Neoplasms*/pathology
Glioblastoma*/diagnostic imaging
Glioblastoma*/genetics
Glioma*/genetics
DNA Methylation ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; Humans ; Machine Learning ; O(6)-Methylguanine-DNA Methyltransferase/genetics ; Retrospective Studies ; Tumor Suppressor Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Significance of MGMT Promoter Methylation Status in Diffuse Glioma.
Autorzy:
Jovanović N; Laboratory for Molecular Biology and Biotechnology, Department of Biology and Ecology, Faculty of Sciences and Mathematics, University of Niš, 18000 Niš, Serbia.
Lazarević M; Laboratory for Molecular Biology and Biotechnology, Department of Biology and Ecology, Faculty of Sciences and Mathematics, University of Niš, 18000 Niš, Serbia.
Cvetković VJ; Laboratory for Molecular Biology and Biotechnology, Department of Biology and Ecology, Faculty of Sciences and Mathematics, University of Niš, 18000 Niš, Serbia.
Nikolov V; Faculty of Medicine, Clinic of Neurosurgery, Clinical Center, University of Niš, 18000 Niš, Serbia.
Kostić Perić J; Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Ugrin M; Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Pavlović S; Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Mitrović T; Laboratory for Molecular Biology and Biotechnology, Department of Biology and Ecology, Faculty of Sciences and Mathematics, University of Niš, 18000 Niš, Serbia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Oct 27; Vol. 23 (21). Date of Electronic Publication: 2022 Oct 27.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Brain Neoplasms*/pathology
Glioma*/pathology
Glioblastoma*/genetics
Humans ; DNA Methylation ; DNA Modification Methylases/genetics ; DNA Repair Enzymes/genetics ; Promoter Regions, Genetic ; Temozolomide/therapeutic use ; O(6)-Methylguanine-DNA Methyltransferase/genetics ; Tumor Suppressor Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
Autorzy:
Chiesa S; Department of Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Mangraviti A; Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Martini M; Depatrment of Pathology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Cenci T; Depatrment of Pathology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Mazzarella C; Department of Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Gaudino S; Department of Radiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Bracci S; Department of Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Martino A; Department of Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Della Pepa GM; Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Offi M; Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Gessi M; Depatrment of Pathology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Russo R; Department of Radiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Martucci M; Department of Radiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Beghella Bartoli F; Department of Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Larocca LM; Depatrment of Pathology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Lauretti L; Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Olivi A; Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Pallini R; Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy. .
Balducci M; Department of Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
D'Alessandris QG; Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Sep 28; Vol. 12 (1), pp. 16265. Date of Electronic Publication: 2022 Sep 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Brain Neoplasms*/pathology
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Glioblastoma*/metabolism
DNA Modification Methylases/genetics ; DNA Repair Enzymes/genetics ; ErbB Receptors/metabolism ; High-Throughput Nucleotide Sequencing ; Humans ; Mitogens ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Phenylurea Compounds ; Prognosis ; Prospective Studies ; Pyridines ; Tumor Suppressor Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 142

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies